利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.072 秒)

    Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
    1.
    发明授权
    Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process 失效
    将胶囊封装在胶囊中的方法和通过这种方法可获得的固体剂型

    公开(公告)号：US06245350B1

    公开(公告)日：2001-06-12

    申请号：US08628823

    申请日：1996-04-05

    申请人： James Amey ,  Dominique Cade ,  Paul Maes ,  Robert Scott

    发明人： James Amey ,  Dominique Cade ,  Paul Maes ,  Robert Scott

    IPC分类号： A61K948

    CPC分类号： A61J3/071 ,  A61J3/07 ,  A61J3/072 ,  A61K9/2072 ,  A61K9/4808 ,  A61K9/4833

    摘要： A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such a process are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.

    摘要翻译： 将胶囊封装在胶囊中的方法包括以下步骤：a。 提供空胶囊零件; b。 用一个或多个囊片填充所述胶囊部件中的至少一个; C。 将胶囊部分放在一起; 和d。 通过冷缩处理组合部件。 通过这种方法可获得的固体剂型是防篡改的，因为它们不能以不重新组装的方式打开，而不显示这种打开过程。

    Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
    2.
    发明授权
    Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process 失效
    将胶囊封装在胶囊中的方法和通过这种方法可获得的固体剂型

    公开(公告)号：US6080426A

    公开(公告)日：2000-06-27

    申请号：US585549

    申请日：1996-01-11

    申请人： James Amey ,  Dominique Cade ,  Paul Maes ,  Robert Scott

    发明人： James Amey ,  Dominique Cade ,  Paul Maes ,  Robert Scott

    IPC分类号： A61J3/07 ,  A61K9/48

    CPC分类号： A61J3/072 ,  A61J3/071 ,  A61K9/4808

    摘要： A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such aprocess are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.

    摘要翻译： 将胶囊封装在胶囊中的方法包括以下步骤：a。 提供空胶囊零件; b。 用一个或多个囊片填充所述胶囊部件中的至少一个; C。 将胶囊部分放在一起; 和d。 通过冷缩处理组合部件。 通过这种处理可获得的固体剂型是防篡改的，因为它们不能以没有显示这种打开过程的方式重新组装而打开。

    Container
    3.
    发明授权
    Container 失效
    容器

    公开(公告)号：US5769267A

    公开(公告)日：1998-06-23

    申请号：US556058

    申请日：1995-11-09

    申请人： Lieven Duynslager ,  Paul Maes ,  Robert Scott ,  Lieve Vanrusselt

    发明人： Lieven Duynslager ,  Paul Maes ,  Robert Scott ,  Lieve Vanrusselt

    IPC分类号： A61J3/07 ,  B65D8/04 ,  B65D55/02 ,  B65D85/00

    CPC分类号： A61J3/071

    摘要： A particular object of the invention is to provide a telescope-type capsule, e.g., for pharmaceutical use or the like, consisting of a cap and a body, the cap having four to six elongated, flat protrusions on its inner wall with a depth of from 30 to 100 .mu.m, preferably 50 to 80 .mu.m, and a length of 1.5 to 3 mm, and a narrowing positioned between the closed end and cylindrically shaped part of the capsule. The narrowing has an area with smaller inclination relative to the capsule axis and an area with stronger inclination which is disposed further away from the open end of the cap than the area with smaller inclination and has a width of 2 to 3 mm and an inclination of 0.03 to 0.07 mm/mm, preferably 0.04 to 0.06 mm/mm. A locking ring with a depth of from 30 to 160 .mu.m, preferably 140 to 120 .mu.m and a width of from 0.8 to 1.2 mm is provided on said narrowing. The body comprises likewise a locking ring, the counter locking ring, which matches the locking ring of the cap and has a depth of 25 to 70 .mu.m and a width of 0.7 to 1.3 mm. Furthermore, at its open end the body is provided with an area of reduced diameter formed by a circular shaped ring with a depth of 10 to 60 .mu.m and a width of 0.8 to 1.4 mm and a wider ring of symmetrical or asymmetrical cross-sectional profile to fit the elongated protrusions.

    摘要翻译： 本发明的一个具体目的是提供一种例如用于医药用途或类似物的望远镜型胶囊，由盖和主体构成，该盖在其内壁上具有四至六个细长的扁平突起，其深度为 30〜100μm，优选为50〜80μm，长度为1.5〜3mm，狭缝位于胶囊的封闭端部和筒状部之间。 狭缝具有相对于胶囊轴线具有较小倾斜度的区域和具有较大倾斜度的区域，该区域设置为比具有较小倾斜度的区域更远离盖的开口端，并且具有2至3mm的宽度和 0.03〜0.07mm / mm，优选为0.04〜0.06mm / mm。 在所述变窄处设置有深度为30〜160μm，优选为140〜120μm，宽度为0.8〜1.2mm的锁定环。 该主体同样包括锁定环，该对置锁定环与帽的锁定环匹配，并且具有25至70μm的深度和0.7至1.3mm的宽度。 此外，在其开口端处，主体设置有由10至60μm的深度和0.8至1.4mm的宽度的圆形环形成的直径减小的区域，以及更宽的对称或不对称横截面的环 以配合细长的突起。

    MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
    6.
    发明申请
    MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE 审中-公开
    至少一种芬替康的形式的改性释放组合物

    公开(公告)号：US20090258067A1

    公开(公告)日：2009-10-15

    申请号：US12425819

    申请日：2009-04-17

    申请人： Fang ZHOU ,  Paul Maes ,  Steven Frisbee

    发明人： Fang ZHOU ,  Paul Maes ,  Steven Frisbee

    IPC分类号： A61K9/24 ,  A61K31/137

    CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2866

    摘要： The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

    摘要翻译： 本发明涉及至少一种形式的文拉法辛的改进释放组合物，其是增强的吸收延迟控释组合物。 组合物包含包含至少一种形式的文拉法辛，小于10％的胶凝剂和药学上可接受的赋形剂的核心。 所述组合物还包含基本上围绕所述芯的改性释放涂层，其提供所述至少一种形式的文拉法辛的延迟控制释放。

    Chronotherapeutic diltiazem formulations and the administration thereof
    7.
    发明授权
    Chronotherapeutic diltiazem formulations and the administration thereof 失效
    计时治疗性地尔硫卓制剂及其施用

    公开(公告)号：US07348028B2

    公开(公告)日：2008-03-25

    申请号：US10657752

    申请日：2003-09-09

    申请人： Kenneth Stephen Albert ,  Theophilus Jones Gana ,  Paul Maes

    发明人： Kenneth Stephen Albert ,  Theophilus Jones Gana ,  Paul Maes

    IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22

    CPC分类号： A61K31/55 ,  A61K9/2081 ,  A61K9/4866 ,  A61K9/5031 ,  A61K9/5047

    摘要： A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans(i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and(ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

    摘要翻译： 一种在有需要的患者中治疗或预防心肌缺血的方法，包括施用药学上可接受的地尔硫卓的可释放的Galenical制剂，包括其药学上可接受的盐，适合于每24小时进行晚间给药，其含有约180mg至约420mg 与给药相关的地尔硫卓形式，以提供受控（持续）释放的地尔硫卓形式，用于在给药后约10小时至约17小时之间在血液中提供地尔硫卓的最大值， 包含地尔硫卓口服持续释放剂型形式的制剂，其中地尔硫卓适于在长时间给药后释放，并在给予人时显示（i）与给予时相比较，在晚上给予时具有较高的生物利用度 在早晨没有食物根据FDA指导方针或标准，和（ii）生物等效性在早晨w给予 根据相同的FDA指南或标准，不含食物。

    Modified release formulations of at least one form of tramadol
    9.
    发明申请
    Modified release formulations of at least one form of tramadol 审中-公开
    至少一种曲马多的缓释制剂

    公开(公告)号：US20050182056A9

    公开(公告)日：2005-08-18

    申请号：US10434266

    申请日：2003-05-09

    申请人： Seth Pawan ,  Paul Maes

    发明人： Seth Pawan ,  Paul Maes

    IPC分类号： A61K9/22 ,  A61K9/28 ,  A61K31/137 ,  A61K31/535 ,  A61K9/20

    CPC分类号： A61K9/2866 ,  A61K9/284 ,  A61K31/137

    摘要： The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37° C.) such that after 2 hours, from about 0% up to about 30% (by weight) of the at least one form of tramadol is released, after 4 hours, from about 5% to about 22% (by weight) of the at least one form of tramadol is released, after 6 hours, from about 15% to about 38% (by weight) of the at least one form of tramadol is released, after 8 hours, more than about 40% (by weight) of the at least one form of tramadol is released.

    摘要翻译： 本发明提供一种包含至少一种形式的曲马多的改性释放药物组合物，其选自曲马多，其对映异构体，其药学上可接受的盐及其组合，所述组合物显示体外溶出曲线（使用USP Basket 方法在75rpm，在900ml 0.1N HCl中于37℃下进行），使得在2小时后，释放至少一种形式的曲马多的约0％至约30％（重量），4小时后， 释放约5％至约22％（重量）的该曲马多的至少一种形式的曲马朵，6小时后，至少一种曲马多的约15％至约38％（重量）被释放， 8小时后，释放至少一种形式的曲马多的大于约40％（重量）。